Company Name Nimbus Discovery
Mailing Address 25 First Street Cambridge, MA 02141
Company Description Nimbus Discovery is applying advances in computer-based drug discovery to unlock fundamental biological pathways. Nimbus has already delivered selective, potent, and differentiated compounds within the first year for two disease targets, IRAK4 and ACC, which are pivotal to the progression of an aggressive subtype of non-Hodgkin’s lymphoma and obesity, respectively.
Proceeds Purposes Proceeds from the financing will be used to accelerate existing programs targeting IRAK4 and ACC, in inflammation, cancer and metabolic disease, and to expand the Nimbus pipeline to include a series of new targets addressing important medical conditions.